Cystic Fibrosis (CF) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

  • Published Date : September 14, 2026
  • Updated On : November 6, 2026
  • Pages : 53

Cystic Fibrosis Unmet Needs and TPP Insights

Thelansis’s “Cystic Fibrosis (CF) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cystic Fibrosis Overview

Cystic fibrosis (CF) is an autosomal recessive multisystem disorder caused by pathogenic CFTR variants that disrupt chloride and bicarbonate transport across epithelial cells. Dehydrated secretions impair mucociliary clearance and obstruct airways and ducts, causing recurrent lung infections, bronchiectasis, pancreatic insufficiency, malabsorption and poor growth; diabetes, liver disease and male infertility may also occur. Care combines airway clearance, exercise, nutrition, pancreatic enzymes when needed, and inhaled or systemic antibiotics for selected infections. CFTR modulators, including elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor, improve protein function in eligible genotypes but do not benefit variants producing no usable CFTR or unresponsive to treatment. Mutation-agnostic approaches, including inhaled mRNA and AAV gene delivery, are in clinical development. No genetic therapy is approved; durable correction remains an unmet need.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Current challenges
    • Unmet needs
  • Emerging therapies
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)

Frequently asked questions